News

Kiromic BioPharma Reaches Resolution with SEC Over Investigation

Kiromic BioPharma Reaches Resolution with SEC Over Investigation

Kiromic BioPharma Settles SEC Investigation

Kiromic BioPharma, Inc. (OTCQB: KRBP) has announced a pivotal resolution to an ongoing investigation by the U.S. Securities and Exchange Commission (SEC). This investigation stemmed from the company's previous executive management failing to disclose crucial details related to clinical holds on its investigational new drug (IND) applications filed with the U.S. Food and Drug Administration (FDA). The IND applications in question related to two key therapies: ALEXIS-PRO-1 and ALEXIS-ISO-1, intended for cancer treatments.

Details of the Settlement

The settlement agreement signifies the end of the SEC's inquiries into Kiromic. Fortunately for the company, the SEC has opted not to impose any civil penalties, primarily due to Kiromic's proactive self-reporting, swift remediation measures, and overall cooperation during the investigation process. As a result, there are currently no ongoing obligations or requirements imposed by the settlement.

Advancements in Biotherapeutics

Kiromic BioPharma is at the forefront of innovation in the biotherapeutics landscape. The company is dedicated to developing advanced allogeneic cell therapy solutions. Utilizing the natural capabilities of Gamma Delta T-cells, Kiromic aims to target solid tumors, which is a significant area of focus in cancer treatment. Their approach represents a cutting-edge strategy that aligns with the evolving field of immuno-oncology.

Innovative Technology with DIAMOND

At the heart of Kiromic's developmental strategy is its proprietary DIAMOND artificial intelligence (AI) platform, specifically version 2.0. This sophisticated technology allows the company to identify and discover novel targets for immuno-oncology treatments. By harnessing the capabilities of AI, Kiromic is positioned to accelerate the research and development of effective therapies.

About Kiromic BioPharma

Headquartered in Houston, Texas, Kiromic BioPharma is a clinical-stage biotherapeutics company that is fully integrated into the therapeutic development process. Their commitment to employing advanced technologies and techniques in their research is a testament to their mission of addressing the challenges in cancer treatment. By tapping into the potential of Gamma Delta T-cells, Kiromic strives to make significant contributions to the medical community and provide innovative solutions to patients.

Connecting with Kiromic

For those interested in keeping up with Kiromic BioPharma, the company maintains an informative online presence. Interested parties can learn more about their advancements and therapeutic developments by visiting their official website and following them on social media platforms like Twitter and LinkedIn. This engagement allows stakeholders and potential investors to stay informed about the latest news and updates from Kiromic.

Frequently Asked Questions

What is the main outcome of Kiromic's settlement with the SEC?

The settlement resolved the SEC investigation without any civil penalties for Kiromic, acknowledging their cooperation and self-reporting.

What are the ALEXIS therapies developed by Kiromic?

ALEXIS-PRO-1 and ALEXIS-ISO-1 are investigational therapies targeting solid tumors, currently under development by Kiromic BioPharma.

How does DIAMOND AI platform contribute to Kiromic's research?

The DIAMOND AI platform helps Kiromic in discovering novel immuno-oncology targets, enhancing the speed and efficacy of therapeutic development.

Where is Kiromic BioPharma headquartered?

Kiromic BioPharma is based in Houston, Texas, where it conducts its clinical-stage biotherapeutics research.

Can investors learn more about Kiromic's updates?

Yes, they can visit Kiromic's official website and follow their social media accounts for the latest news and developments.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Zendure, SolarFlow Pro Win Big at IFA 2026 Tech Awards

Updated Category News Views 2

Trophy Time for Zendure in Berlin The Berlin Chronicles of 2026 tell an interesting tale for Zendure—a tale where top honors and glowing recognition highlight its efforts in the sustainable energy arena. At the Global Product Technology Innovation Awards, Zendure's SolarFlow 4000 Mix Pro snagged the Gold for Sustainable Home Energy Storage System. Not only that, but...

Continue Reading
ATTACK SHARK Partners with Cloud9 League Team

Updated Category News Views 2

Shaking Hands with Cloud9 ATTACK SHARK is jumping headfirst into the esports game, teaming up with Cloud9's League of Legends team. Now, before you roll your eyes at another corporate matchmaking play, consider the magic at play here. League of Legends isn't just any game; it's a titan in the esports universe, and partnering with Cloud9 offers a serious boost. It's not...

Continue Reading
York Space Systems Faces Class Action Over Misleading IPO

Updated Category News Views 2

York Space Systems Under the Legal Spotlight Ever get that feeling when something just doesn’t sit right? Like a burr under the saddle, York Space Systems is now grappling with a class action lawsuit that's throwing a heap of shade on its recent moves. What’s at play? Bronstein, Gewirtz & Grossman, LLC, a law firm that seems to have a nose for corporate messes, has...

Continue Reading
Changhong's IFA 2026 Showcase: AI, Culture & Localization

Updated Category News Views 4

Changhong's Game Plan: From Global Reach to Local Touch Well, Changhong's not sitting back at IFA 2026, let me tell you that. This isn't your run-of-the-mill showcase; it's a full-on reveal of what happens when a company takes AI tech and tunes it to the heartbeat of daily life. TVs, fridges, air conditioners—you name it, they've got an AI twist on it. But is this just...

Continue Reading
TCL’s AI Vision: Immersive Living at IFA 2026

Updated Category News Views 1

AI and Displays: A Match Made in Tech Heaven Every so often, a company stands up at a tech fair and gives a glimpse into the next chapter of living, as TCL did at IFA 2026. This time, they're not just talking about screens; they're weaving them into the fabric of everyday life alongside AI capabilities. From sporting arenas to your living room, it's a vision of what could...

Continue Reading
See's Candies Data Breach Spurs Legal Scrutiny

Updated Category News Views 12

Data Breach Hits See's Candies Hard Amidst Ransomware Attack Alright, folks, here's a not-so-sweet tale to kick off your day — See's Candies has found itself in a bit of a pickle. A ransomware attack, the nasty kind that makes you double-check your locks and your passwords, has reportedly exposed the personal data of its customers and employees. We're talking names,...

Continue Reading
Asia-Pacific Media Forum Eyes Future Growth Strategies

Updated Category News Views 2

Media Heavyweights Converge in Shenzhen Picture this: Over 400 media moguls from the Asia-Pacific region, huddled together in Shenzhen under that blazing September sun. What for? They're on a mission, inspecting China's shifting landscape, hunting down fresh growth avenues in the Guangdong-Hong Kong-Macao Greater Bay Area. It kicks off within the walls of the Asia-Pacific...

Continue Reading
Pudu D7 Robot Shines at IFA, Setting New Robotics Bar

Updated Category News Views 3

Breaking New Ground in Robotics at IFA Well, here's a nugget for robotics buffs and investors alike: Pudu Robotics, a heavyweight in commercial service robotics, is carving out a fresh chapter with its PUDU D7. Making waves as an honoree at the IFA Innovation Awards, the D7 presents a mash-up of brains and brawn—exemplifying the future path for robotics. The PUDU D7...

Continue Reading
DUVA ONE Sleep Earbuds: Real-Time Innovation Debuts

Updated Category News Views 3

While You Dream, DUVA ONE Works Here's the scoop: DUVA just took sleep tech to another level with their DUVA ONE earbuds launched at Berlin's IFA 2026. These aren't just any earbuds; they're engineered to actually do something while you're sleeping. DUVA ONE senses what’s happening during your snooze session and adjusts right on the fly. The Night Patrol: In-Ear and...

Continue Reading
XiamenAir Takes Off with Fujian-London Link

Updated Category News Views 0

A New Dawn for Fujian Travelers Here's a nugget to chew on: XiamenAir's first-ever direct flight from Xiamen to London had its moment in the spotlight. This isn't just another intercontinental flyby—it's a game-changer for folks in Fujian looking to hop across the pond without the layover hassle. With Flight MF821 touching down in Heathrow early on September 6th, this...

Continue Reading

Top 5 Most Recently Viewed Articles

BioCryst Pharmaceuticals Celebrates ORLADEYO's Landmark Approval

Updated Category News Views 152

BioCryst Pharmaceuticals Achieves Significant Reimbursement Milestone BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) has made a significant stride in the healthcare market by securing reimbursement for ORLADEYO (berotralstat) across major European nations. This breakthrough follows a positive recommendation from the Zorginstituut Nederland, leading to ORLADEYO's approval...

Continue Reading
Zoom Communications Achieves Award for Broadcast Innovation Success

Updated Category News Views 296

Zoom Communications Triumphs with Emmy Award Recognition In an impressive showcase of innovation, Zoom Communications, Inc. (NASDAQ: ZM) has received the prestigious Engineering, Science & Technology Emmy® Award. This accolade honors the company's revolutionary Zoom for Broadcast technology, which plays a significant role in enhancing broadcast capabilities across...

Continue Reading
Israel Acquisitions Corp. Reaches New Heights in Stock Prices

Updated Category News Views 46

Israel Acquisitions Corp. Achieves Significant Stock Milestone In a remarkable turn of events, shares of Israel Acquisitions Corp. (ISRL) have soared to a 52-week high, trading at an impressive $11.21. This achievement signifies a crucial milestone in the company's journey, showcasing its robust performance over the past year. The rising confidence among investors is...

Continue Reading
Oculis Advances Transformative Eye Drop Therapy for DME

Updated Category News Views 138

Oculis’ Innovative Approach to Treat Diabetic Macular Edema Oculis Holding AG (Nasdaq: OCS), a pioneering biopharmaceutical company dedicated to enhancing eye health, has made significant strides in treating diabetic macular edema (DME) through its revolutionary OCS-01 eye drops. These high-concentration dexamethasone eye drops are formulated with Oculis' unique...

Continue Reading
Pony AI Inc. Secures Permit for Driverless Robotaxi Services

Updated Category News Views 208

Pony AI Inc. Achieves Major Milestone in Autonomous Mobility Pony AI Inc. has made headlines recently by receiving a permit to operate fully driverless commercial robotaxi services in various urban districts. This remarkable announcement came during a significant event focused on artificial intelligence, signaling an important transition in the way transportation services...

Continue Reading